www.hivandhepatitis.com

HIV Treatment Highlights from IAS 2013 [VIDEO]

Cal Cohen offers a summary of some of the major studies of antiretroviral treatment strategies presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) last week in Kuala Lumpur.

[Cal Cohen, IAS 2013, Kuala Lumpur, July 3, 2013]

While biomedical HIV prevention was a major focus, the conference also included several studies looking at refinements to antiretroviral therapy (ART), including reducing the dose of efavirenz (Sustiva), the new integrase inhibitor dolutegravir, and second-line therapy using raltegravir.

"As mature as our field is, we still continue to learn new things," said Cohen, from the Community Research Initiative of New England.

See also:

IAS 2013: Reduced Efavirenz Dose Suppresses HIV as Well as Standard Dose

IAS 2013: Dolutegravir Superior to Raltegravir for Treatment-experienced People with HIV

IAS 2013: Study Supports WHO Second-line HIV Treatment Guidelines for Resource-limited Countries

7/7/13